allo carts need to make a breakthrough to treat solid tumors. Most allo bios targeting BCMA/CD19 won't survive the bear market. They are still trying to figure out the effective dose and target pts. AUTL and AFMD offer the most promising data IMO
Market Data 
Markets 
AI
